Bay Area companies line up to go public in 2015 – Ardelyx – 10/12
Ardelyx, $69 million: This Fremont biotech led by CEO Michael Raab disclosed its IPO plans on May 19. It develops small molecule treatments for kidney an gastrointestinal disease. Founded: 2007. Funding: About $35 million. Biggest shareholders: New Enterprise Associates (46 percent); CMEA (29 percent) and Amgen Ventures (6 percent).